Background Background Further treatment with
Further treatment with clozapine is contraindicated in any patient clozapine is contraindicated in any patient who has previously experienced who has previously experienced leucopenia or neutropenia during leucopenia or neutropenia during clozapine therapy. clozapine therapy.
Aims
Aims To investigate the results of such a
To investigate the results of such a rechallenge in 53 patients. rechallenge in 53 patients.
Method
Method An analysis was made of the An analysis was made of the demographic, haematological and demographic, haematological and outcome data of patients in the UK and outcome data of patients in the UK and Ireland who were rechallenged with Ireland who were rechallenged with clozapine following leucopenia or clozapine following leucopenia or neutropenia during previous clozapine neutropenia during previous clozapine therapy. therapy.
Results

Results Of 53 patients who were
Of 53 patients who were rechallenged, 20 (38%) experienced a rechallenged, 20 (38%) experienced a further blood dyscrasia.In17 of these 20 further blood dyscrasia.In17 of these 20 patients (85%) the second blood dyscrasia patients (85%) the second blood dyscrasia was more severe ( was more severe (P P5 50.001), in12 (60%) it 0.001), in12 (60%) it lastedlonger ( lastedlonger (P P¼0.0368) andin17 (85%) it 0.0368) andin17 (85%) it occurred more quickly on rechallenge occurred more quickly on rechallenge ( (P P5 50.001).Of the original 53 patients, 0.001).Of the original 53 patients, 55% (29 patients) are still receiving 55% (29 patients) are still receiving clozapine. clozapine.
Conclusions Conclusions No clear risk factor for
No clear risk factor for repeat blood dyscrasias was identified. repeat blood dyscrasias was identified. Despite this, after risks and benefits have Despite this, after risks and benefits have been considered, rechallenge may well be been considered, rechallenge may well be justified in some patients. justified in some patients.
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Clozapine, an atypical antipsychotic agent Clozapine, an atypical antipsychotic agent from the dibenzodiazepine group, is from the dibenzodiazepine group, is indicated for treatment-resistant and indicated for treatment-resistant and treatment-intolerant schizophrenia. In view treatment-intolerant schizophrenia. In view of a risk of agranulocytosis all patients of a risk of agranulocytosis all patients receiving the drug must undergo regular receiving the drug must undergo regular white cell count monitoring. In the UK white cell count monitoring. In the UK and Ireland, until 2004 all patients treated and Ireland, until 2004 all patients treated with clozapine had to be registered with with clozapine had to be registered with and monitored by the Clozaril Patient and monitored by the Clozaril Patient Monitoring Service (CPMS). Since 2004 Monitoring Service (CPMS). Since 2004 generic clozapine has been available and generic clozapine has been available and patients receiving generic drugs are moni-patients receiving generic drugs are monitored by other systems. Clozapine must be tored by other systems. Clozapine must be immediately discontinued if a patient immediately discontinued if a patient develops leucopenia (white cell count develops leucopenia (white cell count 5 53.0 3.06 610 10 9 9 /l with a satisfactory neutrophil /l with a satisfactory neutrophil count) or neutropenia (neutrophil count count) or neutropenia (neutrophil count 5 51.5 1.56 610 10 9 9 /l) and further treatment with /l) and further treatment with clozapine is subsequently contraindicated. clozapine is subsequently contraindicated. However, rechallenge is sometimes consid-However, rechallenge is sometimes considered, as no other antipsychotic has been ered, as no other antipsychotic has been found to be efficacious in treatment-found to be efficacious in treatmentresistant schizophrenia. resistant schizophrenia.
METHOD METHOD
The rechallenge process The rechallenge process in the UK and Ireland in the UK and Ireland Rechallenge with clozapine is an off-label Rechallenge with clozapine is an off-label process undertaken with the assistance of process undertaken with the assistance of the CPMS but at the discretion of the the CPMS but at the discretion of the patient's psychiatrist and at the latter's patient's psychiatrist and at the latter's responsibility. It is generally only in cases responsibility. It is generally only in cases where the neutropenia or leucopenia is where the neutropenia or leucopenia is thought unlikely to have been related to thought unlikely to have been related to clozapine, or in cases of 'mild' neutropenia clozapine, or in cases of 'mild' neutropenia or leucopenia, that clozapine rechallenge is or leucopenia, that clozapine rechallenge is considered. In general, patients who have considered. In general, patients who have experienced agranulocytosis (neutrophil experienced agranulocytosis (neutrophil count count 5 50.5 0.56 610 10 9 9 /l), except in association /l), except in association with chemotherapy, are not thought with chemotherapy, are not thought suitable for rechallenge. suitable for rechallenge.
Study method Study method
Patients in the UK and Ireland who, Patients in the UK and Ireland who, between 1998 (when a formal rechallenge between 1998 (when a formal rechallenge process was instituted) and 2003, were re-process was instituted) and 2003, were rechallenged with clozapine following leuco-challenged with clozapine following leucopenia or neutropenia during previous penia or neutropenia during previous clozapine therapy were identified from the clozapine therapy were identified from the CPMS database. Patients were required to CPMS database. Patients were required to have had a break of at least 1 week between have had a break of at least 1 week between their two courses of treatment in order to their two courses of treatment in order to be classified as rechallenge patients. Infor-be classified as rechallenge patients. Information on demographic factors (age, gen-mation on demographic factors (age, gender and ethnic origin), clozapine treatment der and ethnic origin), clozapine treatment and haematolgical history and outcome of and haematolgical history and outcome of these patients was gathered from the CPMS these patients was gathered from the CPMS database. Clinical information, particularly database. Clinical information, particularly information concerning any other possible information concerning any other possible causes for the blood dyscrasias, was ob-causes for the blood dyscrasias, was obtained from clinician correspondence and tained from clinician correspondence and notes made at the time by the CPMS notes made at the time by the CPMS following discussions with healthcare following discussions with healthcare teams. teams.
Statistical analysis Statistical analysis
In the analysis of our results we considered In the analysis of our results we considered the following three main groups of patients: the following three main groups of patients:
(a) (a) all 53 patients who were rechallenged; all 53 patients who were rechallenged;
(b) (b) patients who experienced a further patients who experienced a further blood dyscrasia on rechallenge; blood dyscrasia on rechallenge;
(c) (c) patients who did not develop a blood patients who did not develop a blood dyscrasia on rechallenge. dyscrasia on rechallenge.
We further considered the group that We further considered the group that experienced agranulocytosis on rechal-experienced agranulocytosis on rechallenge. lenge.
Statistical analysis was carried out Statistical analysis was carried out using SAS version 8.2 for Windows (SAS using SAS version 8.2 for Windows (SAS Institute Inc., Cary, North Carolina, Institute Inc., Cary, North Carolina, USA). Comparisons were made between USA). Comparisons were made between patients who experienced a second dyscra-patients who experienced a second dyscrasia sia v v. those who did not, using the Wilcox-. those who did not, using the Wilcoxon two-sample test or chi-squared test on two-sample test or chi-squared test (categorical variables). Within-subject com-(categorical variables). Within-subject comparisons for characteristics of first and parisons for characteristics of first and second dyscrasias were made using the second dyscrasias were made using the Wilcoxon signed ranks test. Time to Wilcoxon signed ranks test. Time to occurrence of dyscrasia was analysed using occurrence of dyscrasia was analysed using the Kaplan-Meier product-limit method the Kaplan-Meier product-limit method with between-group differences tested using with between-group differences tested using the log-rank test. All reported the log-rank test. All reported P P values are values are two-sided. two-sided.
RESULTS
Rechallenge patients: Rechallenge patients: demographics and data demographics and data on original dyscrasia on original dyscrasia
We identified 53 patients (16 women, 37 We identified 53 patients (16 women, 37 men) who had been rechallenged with men) who had been rechallenged with clozapine following a confirmed blood clozapine following a confirmed blood dyscrasia. All of them had a diagnosis dyscrasia. All of them had a diagnosis of treatment-resistant schizophrenia. The of treatment-resistant schizophrenia. The ( 2 0 0 6 ) , 1 8 8 , 2 5 5^2 6 3
Rechallenge with clozapine following leucopenia Rechallenge with clozapine following leucopenia or neutropenia during previous therapy or neutropenia during previous therapy median age of the cohort was 34 years median age of the cohort was 34 years (range 20-61). The ethnic backgrounds of (range 20-61). The ethnic backgrounds of the patients were 41 (77%) White, 7 the patients were 41 (77%) White, 7 (13%) African-Caribbean, 3 (6%) 'Asian', (13%) African-Caribbean, 3 (6%) 'Asian', 1 (2%) 'Oriental' and 1 (2%) mixed ethni-1 (2%) 'Oriental' and 1 (2%) mixed ethnicity. All of the three main groups of patients city. All of the three main groups of patients in our study were found to be alike demo-in our study were found to be alike demographically. Data on the first-exposure graphically. Data on the first-exposure blood dyscrasia experienced by these pa-blood dyscrasia experienced by these patients are presented in the second column tients are presented in the second column of Table 1 . The duration of clozapine treat-of Table 1 . The duration of clozapine treatment at the time of the blood dyscrasias ment at the time of the blood dyscrasias indicates that this group is not typical of indicates that this group is not typical of patients who have experienced clozapine-patients who have experienced clozapineinduced blood dyscrasias, for whom the induced blood dyscrasias, for whom the peak incidence occurs at 6-18 weeks (Mun-peak incidence occurs at 6-18 weeks (Munro ro et al et al, 1999) . Twenty-eight (53%) of the , 1999). Twenty-eight (53%) of the patients had no alternative explanation for patients had no alternative explanation for the blood dyscrasia. In 13 (25%) concur-the blood dyscrasia. In 13 (25%) concurrent infection was reported, 9 (17%) were rent infection was reported, 9 (17%) were taking concurrent medication recognised taking concurrent medication recognised to cause neutropenia, and 3 (6%) had both to cause neutropenia, and 3 (6%) had both these risk factors (Table 2 ). In two patients these risk factors (Table 2 ). In two patients the blood dyscrasias had been treated the blood dyscrasias had been treated with granulocyte colony-stimulating factor with granulocyte colony-stimulating factor (G-CSF). (G-CSF).
Patients experiencing Patients experiencing a further blood dyscrasia a further blood dyscrasia
Of the 53 patients, 20 (5 women, 15 men) Of the 53 patients, 20 (5 women, 15 men) (38%) experienced a further blood dyscra-(38%) experienced a further blood dyscrasia on rechallenge. The median age of these sia on rechallenge. The median age of these patients was 36 years (range 25-60) and the patients was 36 years (range 25-60) and the ethnicity of the group was 17 (85%) White, ethnicity of the group was 17 (85%) White, 2 (10%) African-Caribbean and 1 (5%) 2 (10%) African-Caribbean and 1 (5%) 'Asian'. Table 1 summarises the data avail-'Asian'. Table 1 summarises the data available for the original blood dyscrasia for the able for the original blood dyscrasia for the three main groups: all 53 patients, the 20 three main groups: all 53 patients, the 20 patients who developed a blood dyscrasia patients who developed a blood dyscrasia on rechallenge and the 33 patients who on rechallenge and the 33 patients who did not. There was no statistically did not. There was no statistically significant difference between those who significant difference between those who developed dyscrasia on rechallenge and developed dyscrasia on rechallenge and those who did not in duration of clozapine those who did not in duration of clozapine treatment at the time of the original treatment at the time of the original blood dyscrasia ( blood dyscrasia (P P¼0.50), number of 0.50), number of patients in whom no alternative explana-patients in whom no alternative explanation for the original blood dyscrasia was tion for the original blood dyscrasia was recorded ( recorded (P P¼0.054) or duration of 0.054) or duration of clozapine treatment break ( clozapine treatment break (P P¼0.93). 0.93).
Nine (45%) of the second blood dyscra-Nine (45%) of the second blood dyscrasias were neutropenias, 2 (10%) were leuco-sias were neutropenias, 2 (10%) were leucopenias and 9 (45%) were agranulocytoses. penias and 9 (45%) were agranulocytoses. Data on these second blood dyscrasias are Data on these second blood dyscrasias are presented in Table 3 . The median time for presented in Table 3 . The median time for the blood dyscrasias to develop from the the blood dyscrasias to develop from the time of restarting clozapine was 5.5 weeks time of restarting clozapine was 5.5 weeks and in 80% ( and in 80% (n n¼16) of the 20 patients the 16) of the 20 patients the second blood dyscrasia occurred within 10 second blood dyscrasia occurred within 10 weeks of restarting clozapine (Fig. 1 ). Six-weeks of restarting clozapine (Fig. 1 ). Sixteen (80%) patients had no alternative ex-teen (80%) patients had no alternative explanation for this second blood dyscrasia. planation for this second blood dyscrasia. Two (10%) reported a concurrent infec-Two (10%) reported a concurrent infection, 1 (5%) was receiving a concomitant tion, 1 (5%) was receiving a concomitant medication recognised to cause neutropenia medication recognised to cause neutropenia and 1 (5%) had both these risk factors and 1 (5%) had both these risk factors 2 5 6 2 5 6 (Table 4 ). Five patients received G-CSF as (Table 4 ). Five patients received G-CSF as treatment for the second blood dyscrasia. treatment for the second blood dyscrasia. In all of the 20 patients the blood dyscrasia In all of the 20 patients the blood dyscrasia remitted when they again stopped taking remitted when they again stopped taking clozapine; there was no fatality. None of clozapine; there was no fatality. None of the 20 patients subsequently restarted the 20 patients subsequently restarted clozapine. clozapine.
Comparison of first and second blood Comparison of first and second blood dyscrasias dyscrasias
In all but 3 of the 20 patients (85%) the sec-In all but 3 of the 20 patients (85%) the second blood dyscrasia occurred more quickly ond blood dyscrasia occurred more quickly than the first, and overall the time to the than the first, and overall the time to the second blood dyscrasia was much less than second blood dyscrasia was much less than the time to the first (median time 5.5 weeks the time to the first (median time 5.5 weeks for the second dyscrasia compared with for the second dyscrasia compared with 81.5 weeks for the first dyscrasia in these 81.5 weeks for the first dyscrasia in these 20 patients; 20 patients; P P5 50.001). This is strikingly 0.001). This is strikingly illustrated by the Kaplan-Meier plot in illustrated by the Kaplan-Meier plot in Fig. 2 . Again in all but 3 (85%) -but in Fig. 2 . Again in all but 3 (85%) -but in different patients -the second blood dys-different patients -the second blood dyscrasia was more severe than the first (nadir crasia was more severe than the first (nadir neutrophil count lower than during the first neutrophil count lower than during the first blood dyscrasia; blood dyscrasia; P P5 50.001), and in all but 8 0.001), and in all but 8 (60%) the second blood dyscrasia lasted (60%) the second blood dyscrasia lasted longer than the first (one of the patients longer than the first (one of the patients whose second blood dyscrasia was shorter whose second blood dyscrasia was shorter was treated with G-CSF); was treated with G-CSF); P P¼0.0368. Fig-0 .0368. Figures 3-5 compare the time to onset, severity ures 3-5 compare the time to onset, severity and duration of the first and second blood and duration of the first and second blood dyscrasias in the 20 patients who experi-dyscrasias in the 20 patients who experienced a blood dyscrasia on rechallenge. enced a blood dyscrasia on rechallenge. The patients identified by the numbers The patients identified by the numbers 1-9 1-9 are those who developed agranulocytosis are those who developed agranulocytosis on rechallenge. on rechallenge.
Patients who developed agraunulocytosis
Patients who developed agraunulocytosis Table 5 lists the nine patients who devel- Table 5 lists the nine patients who developed agranulocytosis on rechallenge. It pro-oped agranulocytosis on rechallenge. It provides background data including factors vides background data including factors that can be considered likely to predict that can be considered likely to predict agranulocytosis on rechallenge. Both men agranulocytosis on rechallenge. Both men and women are represented and the median and women are represented and the median age is 38 years (range 27-59). All of these age is 38 years (range 27-59). All of these patients were White and all experienced a patients were White and all experienced a neutropenia on first exposure. The median neutropenia on first exposure. The median clozapine dosage at the time of the first clozapine dosage at the time of the first blood dyscrasia for these patients was blood dyscrasia for these patients was 400 mg per day (range 0-800). None of 400 mg per day (range 0-800). None of the patients received G-CSF as treatment the patients received G-CSF as treatment for their first blood dyscrasia. The duration for their first blood dyscrasia. The duration of the first exposure demonstrates that six of the first exposure demonstrates that six of the first blood dyscrasias in this group of the first blood dyscrasias in this group could be considered atypical of clozapine-could be considered atypical of clozapineinduced dyscrasias as they occurred after a induced dyscrasias as they occurred after a year of treatment, well outside the peak risk year of treatment, well outside the peak risk period. However, there were potential risk period. However, there were potential risk factors for rechallenge in some of the factors for rechallenge in some of the patients, as three of the first blood dyscra-patients, as three of the first blood dyscrasias occurred during the peak risk period, sias occurred during the peak risk period, four had a duration of more than 3 days four had a duration of more than 3 days and three had a nadir neutrophil count and three had a nadir neutrophil count below 1.0 below 1.06 610 10 9 9 /l. However, no one patient /l. However, no one patient demonstrated all three of these potential demonstrated all three of these potential risk factors and patients 2, 4 and 6 demon-risk factors and patients 2, 4 and 6 demonstrated none of them. The median duration strated none of them. The median duration of break in clozapine treatment for these of break in clozapine treatment for these nine patients was 14 weeks (range 5-337). nine patients was 14 weeks (range 5-337). Table 6 provides the data available for Table 6 provides the data available for the repeat-exposure blood dyscrasia for the repeat-exposure blood dyscrasia for the same nine patients. The median age is the same nine patients. The median age is still 38 years (range 29-60). The speed of still 38 years (range 29-60). The speed of onset (all dyscrasias occurred 4-6 weeks onset (all dyscrasias occurred 4-6 weeks after rechallenge), duration (in all but one after rechallenge), duration (in all but one case the dyscrasia lasted more than 3 days) case the dyscrasia lasted more than 3 days) and severity of the blood dyscrasias are and severity of the blood dyscrasias are notable. The median dosage at the time of notable. The median dosage at the time of 2 5 7 2 5 7 the second blood dyscrasia was 300 mg per the second blood dyscrasia was 300 mg per day (range 0-700); for 2 patients dosage day (range 0-700); for 2 patients dosage was not recorded. was not recorded.
Patient rechallenged after agranulocytosis Patient rechallenged after agranulocytosis during first treatment during first treatment
The patient who had an agranulocytosis on The patient who had an agranulocytosis on first exposure did not develop a blood first exposure did not develop a blood dyscrasia on second exposure during the dyscrasia on second exposure during the period of data collection. However, he de-period of data collection. However, he developed neutropenia, which resolved when veloped neutropenia, which resolved when clozapine administration was stopped, after clozapine administration was stopped, after the cut-off point for data collection, 4 the cut-off point for data collection, 4 weeks after he restarted clozapine. At the weeks after he restarted clozapine. At the time of this second blood dyscrasia the time of this second blood dyscrasia the patient had a cough, a shadow on chest patient had a cough, a shadow on chest X-ray, and was prescribed antibiotics. X-ray, and was prescribed antibiotics.
Patients who did not develop Patients who did not develop a blood dyscrasia on rechallenge a blood dyscrasia on rechallenge
Thirty-three patients (62%) (11 women, 22 Thirty-three patients (62%) (11 women, 22 men) did not develop a second blood dys-men) did not develop a second blood dyscrasia during rechallenge with clozapine. crasia during rechallenge with clozapine. The median age of these patients was 33
The median age of these patients was 33 years (range 20-61), and the ethnicity of years (range 20-61), and the ethnicity of this group was 24 (73%) White, 5 (15%) this group was 24 (73%) White, 5 (15%) African-Caribbean, 2 (6%) 'Asian', 1 African-Caribbean, 2 (6%) 'Asian', 1 (3%) 'Oriental' and 1 (3%) mixed ethni-(3%) 'Oriental' and 1 (3%) mixed ethnicity. The median daily dosage of clozapine city. The median daily dosage of clozapine at the study cut-off point or at the time at the study cut-off point or at the time the patient discontinued clozapine was the patient discontinued clozapine was 400 mg (range 200-800); in 3 patients 400 mg (range 200-800); in 3 patients dosage was not recorded. Twenty-nine dosage was not recorded. Twenty-nine (88%) of these 33 patients were still receiv-(88%) of these 33 patients were still receiving clozapine at the time of writing. The ing clozapine at the time of writing. The median duration of the second exposure median duration of the second exposure in these 29 patients was 24 months (range in these 29 patients was 24 months (range 1-58); Fig. 6 . Of the four patients no longer 1-58); Fig. 6 . Of the four patients no longer receiving clozapine, two died: the first 2.5 receiving clozapine, two died: the first 2.5 months after restarting clozapine, from months after restarting clozapine, from chronic obstructive airways disease and chronic obstructive airways disease and ischaemic heart disease due to coronary ar-ischaemic heart disease due to coronary artery atheroma; the second 6.5 months after tery atheroma; the second 6.5 months after restarting clozapine, from acute pulmonary restarting clozapine, from acute pulmonary oedema, bilateral pleural effusions and oedema, bilateral pleural effusions and ascites, presumed toxic effect of pneumo-ascites, presumed toxic effect of pneumococcal pneumonia, glomerulosclerosis or coccal pneumonia, glomerulosclerosis or pseudomembranous colitis. One patient pseudomembranous colitis. One patient discontinued clozapine owing to the occur-discontinued clozapine owing to the occurrence of chest pain 29 months after restart-rence of chest pain 29 months after restarting, and the fourth patient stopped ing, and the fourth patient stopped clozapine 1 month after restarting in view clozapine 1 month after restarting in view of an overdue blood test. Thus, of the origi-of an overdue blood test. Thus, of the original 53 patients, more than half (55%; nal 53 patients, more than half (55%; n n¼29) were still receiving clozapine in 29) were still receiving clozapine in February 2005. February 2005. 
DISCUSSION DISCUSSION
Since the grant of the clozapine licence in Since the grant of the clozapine licence in the UK in 1989, and in Ireland in 1993, the UK in 1989, and in Ireland in 1993, until 1 December 2003, a total of 38 106 until 1 December 2003, a total of 38 106 patients in these countries received cloza-patients in these countries received clozapine. Within this cohort there have been pine. Within this cohort there have been 688 (1.8%) cases of neutropenia (neutro-688 (1.8%) cases of neutropenia (neutrophil count 0.5-1.5 phil count 0.5-1.56 610 10 9 9 /l), 72 (0.19%) /l), 72 (0.19%) cases of leucopenia and 298 (0.78%) cases cases of leucopenia and 298 (0.78%) cases of agranulocytosis. There have been three of agranulocytosis. There have been three deaths attributed to agranulocytosis (in deaths attributed to agranulocytosis (in one the white cell count had begun to rise one the white cell count had begun to rise before the patient died; Mangan & Toal, before the patient died; Mangan & Toal, 1994) . The last of these deaths was in 1998. 1994). The last of these deaths was in 1998.
Clozapine-induced agranulocytosis Clozapine-induced agranulocytosis
Agranulocytosis associated with clozapine Agranulocytosis associated with clozapine is an idiosyncratic (type B) reaction and is is an idiosyncratic (type B) reaction and is not dose-related, as previous analysis of not dose-related, as previous analysis of the CPMS cohort has shown (Munro the CPMS cohort has shown (Munro et al et al, , 1999) . The toxicity mainly affects the mye-1999). The toxicity mainly affects the myeloid (neutrophil) precursor cells, although loid (neutrophil) precursor cells, although the mature neutrophil may also be affected the mature neutrophil may also be affected simultaneously (Pirmohamed & Park, simultaneously (Pirmohamed & Park, 1997) . Seventy per cent of cases occur 1997). Seventy per cent of cases occur 6-18 weeks after the start of treatment 6-18 weeks after the start of treatment (Munro (Munro et al et al, 1999) . Although the risk of , 1999). Although the risk of agranulocytosis decreases with time, some agranulocytosis decreases with time, some cases are reported after a number of years cases are reported after a number of years of continued therapy. The mechanism of of continued therapy. The mechanism of clozapine-induced agranulocytosis is not clozapine-induced agranulocytosis is not known but some evidence favours an known but some evidence favours an immune-mediated mechanism that may immune-mediated mechanism that may involve a toxic metabolite (Pirmohamed involve a toxic metabolite (Pirmohamed & Park, 1997) . The disorder is reversible & Park, 1997). The disorder is reversible in the vast majority of cases if clozapine in the vast majority of cases if clozapine is withdrawn promptly. Supportive care, is withdrawn promptly. Supportive care, such as reverse isolation and treatment with such as reverse isolation and treatment with G-CSF or granulocyte-macrophage colony-G-CSF or granulocyte-macrophage colonystimulating factor (GM-CSF), antibiotics stimulating factor (GM-CSF), antibiotics and antifungals as appropriate, may be and antifungals as appropriate, may be required. The CPMS data indicate an required. The CPMS data indicate an increased risk of agranulocytosis with increased risk of agranulocytosis with increasing age and Asian ethnicity (Munro increasing age and Asian ethnicity (Munro et al et al, 1999) . Additionally, some authors , 1999). Additionally, some authors have suggested an increased risk in women have suggested an increased risk in women (Alvir & Lieberman, 1994) , although this (Alvir & Lieberman, 1994) , although this was not seen in the UK CPMS cohort, and was not seen in the UK CPMS cohort, and in people of Ashkenazi Jewish descent with in people of Ashkenazi Jewish descent with the haplotype HLA-B38, DR4, DQw3 the haplotype HLA-B38, DR4, DQw3 (Lieberman (Lieberman et al et al, 1990) . Concomitant , 1990) . Concomitant treatment with other drugs reported to treatment with other drugs reported to cause leucopenia may also increase the risk cause leucopenia may also increase the risk of agranulocytosis (Idanpaan-Heikkila of agranulocytosis (Idä npä ä n-Heikkilä et et al al, 1977; Povlsen , 1977; Povlsen et al et al, 1985; Lindstrom, , 1985; Lindströ m, 1988; Gerson 1988; Gerson et al et al, 1991; Gerson & , 1991 ; Gerson & 2 5 9 2 5 9 , 1992; Junghan Meltzer, 1992; Junghan et al et al, 1993; , 1993; Valevski Valevski et al et al, 1993; Chengappa , 1993; Chengappa et al et al, , 1996; Senechal 1996; Sénéchal et al et al, 2002) , as perhaps does , 2002), as perhaps does a history of drug-induced blood dyscrasias a history of drug-induced blood dyscrasias (Idanpaan-Heikkila (Idä npä ä n-Heikkilä et al et al, 1977; Valevski , 1977; Valevski et al et al, 1993) .
Meltzer
, 1993).
Previous rechallenge experience Previous rechallenge experience
We identified 12 published reports (37 pa-We identified 12 published reports (37 patients) providing information on outcome tients) providing information on outcome in patients rechallenged with clozapine in patients rechallenged with clozapine after previous leucopenias, neutropenias after previous leucopenias, neutropenias or agranulocytoses during clozapine treat-or agranulocytoses during clozapine treatment (Idanpaan-Heikkila ment (Idä npä ä n-Heikkilä et al et al, 1977; , 1977; Povlsen Povlsen et al et al, 1985; Lindstrom, 1988; , 1985; Lindströ m, 1988; Grohmann Grohmann et al et al, 1989; Safferman , 1989; Safferman et al et al, , 1992 Safferman et al et al, , , 1993 Frankenberg 1992 Frankenberg , 1993 Frankenberg et al et al, 1994; Bar-, 1994; Barrons rons et al et al, 1996; Chengappa , 1996; Chengappa et al et al, 1996; Sperner-Unterweger Sperner-Unterweger et al et al, 1998; Senechal , 1998; Sénéchal et al et al, 2002; Ahn , 2002; Ahn et al et al, 2004) . Five reports , 2004) . Five reports (14 patients) described unsuccessful cloza-(14 patients) described unsuccessful clozapine rechallenge. We are defining successful pine rechallenge. We are defining successful rechallenge as re-exposure that does not re-rechallenge as re-exposure that does not result in leucopenia, neutropenia or agranulo-sult in leucopenia, neutropenia or agranulocytosis or re-exposure where the patient is cytosis or re-exposure where the patient is maintained on clozapine and ultimately maintained on clozapine and ultimately has a normal white cell and neutrophil has a normal white cell and neutrophil count. Five of the eight reports of successful count. Five of the eight reports of successful rechallenge were of unconventional proce-rechallenge were of unconventional procedures: one described a clozapine overdose dures: one described a clozapine overdose after clozapine discontinuation, and in four after clozapine discontinuation, and in four clozapine was not discontinued despite low clozapine was not discontinued despite low white cell or neutrophil counts. All 12 white cell or neutrophil counts. All 12 reports are summarised in Table 7 . reports are summarised in Table 7 .
Two types of clozapine-induced Two types of clozapine-induced neutropenia? neutropenia?
It has been postulated that clozapine can in-It has been postulated that clozapine can induce two clinically distinct types of neutro-duce two clinically distinct types of neutropenia (Gerson, 1993 ; the first type is penia (Gerson, 1993 ; the first type is a mild to moderate neutropenia (neutrophil a mild to moderate neutropenia (neutrophil count below 1.5 count below 1.56 610 10 9 9 /l but not lower than /l but not lower than 0.5 0.56 610 10 9 9 /l), which occurs in 1.8% of /l), which occurs in 1.8% of treated patients. When clozapine is discon-treated patients. When clozapine is discontinued, recovery is rapid (2-8 days). The tinued, recovery is rapid (2-8 days). The second type of neutropenia is more severe second type of neutropenia is more severe with a neutrophil count below 0.5 with a neutrophil count below 0.56 610 10 9 9 /l /l (agranulocytosis) and an incidence of (agranulocytosis) and an incidence of 0.78%. In the second type, even if cloza-0.78%. In the second type, even if clozapine is stopped when the neutrophil count pine is stopped when the neutrophil count is just below 1.5 is just below 1.56 610 10 9 9 /l, agranulocytosis /l, agranulocytosis none the less develops in some patients, none the less develops in some patients, usually within 2-5 days and generally usually within 2-5 days and generally lasting for 14-21 days. In such patients, lasting for 14-21 days. In such patients, monitoring allows the early detection and monitoring allows the early detection and 2 6 0 2 6 0 2 61 2 61 
1 1 Two episodes of neutropenia, one after 5 years, the other after 7 years. Both Two episodes of neutropenia, one after 5 years, the other after 7 years. Both attributed to addition of other drugs to clozapine regimen (haloperidol in first attributed to addition of other drugs to clozapine regimen (haloperidol in first instance, risperidone in second) instance, risperidone in second) Clozapine appears to have been continued throughout. Both neutropenias Clozapine appears to have been continued throughout. Both neutropenias resolved, in second instance 12 days after discontinuation of risperidone resolved, in second instance 12 days after discontinuation of risperidone Ahn Ahn et al et al (2004) 
5 5 All maintained on clozapine despite an episode of neutropenia All maintained on clozapine despite an episode of neutropenia In all 5, no further neutropenia occurred during the observation period (at least In all 5, no further neutropenia occurred during the observation period (at least 600 days) despite continuation of clozapine 600 days) despite continuation of clozapine G-CSF, granulocyte colony-stimulating factor; WCC, white cell count. G-CSF, granulocyte colony-stimulating factor; WCC, white cell count.
treatment but not the prevention of neutro-treatment but not the prevention of neutrophil suppression. Bone marrow from these phil suppression. Bone marrow from these patients demonstrates an absence of patients demonstrates an absence of myeloid precursors, only occasional pro-myeloid precursors, only occasional promyelocytes and myeloblasts, and relative myelocytes and myeloblasts, and relative erythroid hyperplasia (Gerson & Meltzer, erythroid hyperplasia (Gerson & Meltzer, 1992) . In contrast, in the milder cloza-1992). In contrast, in the milder clozapine-induced neutropenia, it has been re-pine-induced neutropenia, it has been reported that there is evidence of myeloid ported that there is evidence of myeloid maturation in the bone marrow, suggesting maturation in the bone marrow, suggesting peripheral destruction of neutrophils peripheral destruction of neutrophils (Gerson, 1993) . The theory is compatible (Gerson, 1993) . The theory is compatible with the fact that, despite a considerable with the fact that, despite a considerable decrease in the incidence of fatal cloza-decrease in the incidence of fatal clozapine-induced agranulocytosis since the pine-induced agranulocytosis since the onset of white cell count monitoring -from onset of white cell count monitoring -from 0.26% in Finland in 1975 (Idanpaan-0.26% in Finland in 1975 (Idä npä ä n-Heikkila Heikkilä et al et al, 1977 to 0.01% in the UK , 1977) to 0.01% in the UK and Ireland with monitoring -the inci-and Ireland with monitoring -the incidence of agranulocytosis has remained dence of agranulocytosis has remained fairly constant and has not decreased: a fairly constant and has not decreased: a cautious estimate of 0.5% in Finland in cautious estimate of 0.5% in Finland in 1975 (Idanpaan-Heikkila 1975 (Idä npä ä n-Heikkilä et al et al, 1977 as , 1977 ; as there was no routine monitoring some cases there was no routine monitoring some cases are likely to have missed identification), are likely to have missed identification), 0.78% in the UK and Ireland with monitor-0.78% in the UK and Ireland with monitoring. However, it does not seem compatible ing. However, it does not seem compatible with the results we have presented, as one with the results we have presented, as one would not expect patients who had experi-would not expect patients who had experienced only neutropenia or leucopenia on enced only neutropenia or leucopenia on first exposure to clozapine to develop agra-first exposure to clozapine to develop agranulocytosis on second exposure, unless they nulocytosis on second exposure, unless they had somehow become more sensitive to had somehow become more sensitive to clozapine bone-marrow toxicity. It also im-clozapine bone-marrow toxicity. It also implies that patients who develop only neutro-plies that patients who develop only neutropenia or leucopenia on first exposure to penia or leucopenia on first exposure to clozapine can be relatively safely rechal-clozapine can be relatively safely rechallenged, and our results demonstrate that lenged, and our results demonstrate that this is not the case, with nine this is not the case, with nine patients patients who experienced a neutropenia on who experienced a neutropenia on first first exposure developing agranulocytosis on exposure developing agranulocytosis on repeat exposure. repeat exposure.
Mechanism of clozapine-induced Mechanism of clozapine-induced agranulocytosis agranulocytosis
The exact mechanism of clozapine-induced The exact mechanism of clozapine-induced agranulocytosis is unknown; it could be agranulocytosis is unknown; it could be immune-mediated or involve a toxic me-immune-mediated or involve a toxic mechanism, or even a combination of both. chanism, or even a combination of both. In the group of nine patients unsuccessfully In the group of nine patients unsuccessfully rechallenged with clozapine by Safferman rechallenged with clozapine by Safferman et al et al (1992) , blood dyscrasias recurred after (1992), blood dyscrasias recurred after a number of weeks, with an average time to a number of weeks, with an average time to onset of 14.6 weeks. These authors onset of 14.6 weeks. These authors concluded that their data favoured an concluded that their data favoured an immune-mediated mechanism, because the immune-mediated mechanism, because the blood dyscrasias recurred in all nine pa-blood dyscrasias recurred in all nine patients and did so more quickly on repeat tients and did so more quickly on repeat exposure. The single case report by exposure. The single case report by Frankenberg Frankenberg et al et al (1994) also documents (1994) also documents a more rapid blood dyscrasia on re-a more rapid blood dyscrasia on rechallenge. Our findings differ from those challenge. Our findings differ from those of Safferman of Safferman et al et al (1992) as blood dyscra-(1992) as blood dyscrasias recurred in only 38% of the 53 patients sias recurred in only 38% of the 53 patients rechallenged in our study, and we found rechallenged in our study, and we found that the median time to onset of the rechal-that the median time to onset of the rechallenge dyscrasia was 5.5 weeks, with 80% of lenge dyscrasia was 5.5 weeks, with 80% of cases, including all the cases of agranulocy-cases, including all the cases of agranulocytosis, occurring before 10 weeks. However, tosis, occurring before 10 weeks. However, we did find that when blood dyscrasias we did find that when blood dyscrasias occurred on rechallenge they tended to occurred on rechallenge they tended to happen more quickly, last longer and be happen more quickly, last longer and be more severe. Our results, therefore, also more severe. Our results, therefore, also suggest an immune-mediated mechanism, suggest an immune-mediated mechanism, but as the blood dyscrasias occurred weeks but as the blood dyscrasias occurred weeks rather than days after rechallenge, a simple rather than days after rechallenge, a simple immunological toxicity cannot be the immunological toxicity cannot be the mechanism. It might be that a certain mechanism. It might be that a certain concentration of metabolite needs to accu-concentration of metabolite needs to accumulate in order to stimulate an immunolo-mulate in order to stimulate an immunologically mediated toxicity. Whatever the gically mediated toxicity. Whatever the mechanism, it is clear that extreme caution mechanism, it is clear that extreme caution is required when rechallenging a patient is required when rechallenging a patient with clozapine. with clozapine.
Implications of our findings Implications of our findings
The results we have described represent the The results we have described represent the first published report of a well-documented first published report of a well-documented cohort of patients who have been rechal-cohort of patients who have been rechallenged with a good degree of success. This lenged with a good degree of success. This is due in part to the careful selection of pa-is due in part to the careful selection of patients on the basis that their initial blood tients on the basis that their initial blood dyscrasia might well have had a cause other dyscrasia might well have had a cause other than clozapine and/or that they had experi-than clozapine and/or that they had experienced a 'mild' episode. Despite this, 38% enced a 'mild' episode. Despite this, 38% ( (n n¼20) of our patients did experience a 20) of our patients did experience a second blood dyscrasia and 45% ( second blood dyscrasia and 45% (n n¼9) of 9) of these patients developed agranulocytosis, these patients developed agranulocytosis, which represents a 22-fold increase in risk which represents a 22-fold increase in risk of agranulocytosis in our rechallenge group of agranulocytosis in our rechallenge group compared with clozapine-naıve patients (in compared with clozapine-naïve patients (in clozapine-naıve patients, 2.8% of patients clozapine-naïve patients, 2.8% of patients would be expected to develop a blood dys-would be expected to develop a blood dyscrasia, of whom 28% would be expected to crasia, of whom 28% would be expected to Clozapine rechallenge should not be undertaken lightly, because patients rechallenged with clozapine are considerably more likely to develop a further blood rechallenged with clozapine are considerably more likely to develop a further blood dyscrasia, and specifically are 22 times more likely to develop an agranulocytosis, than dyscrasia, and specifically are 22 times more likely to develop an agranulocytosis, than clozapine-na|ve patients. clozapine-na|« ve patients.
& & The first 10 weeks of rechallenge are critical as most blood dyscrasias are likely to
The first 10 weeks of rechallenge are critical as most blood dyscrasias are likely to become apparent within this time. become apparent within this time.
& & In a carefully selected group rechallenge may well be justified if it is considered that In a carefully selected group rechallenge may well be justified if it is considered that the risks of withholding treatment are greater than the risks of rechallenge. the risks of withholding treatment are greater than the risks of rechallenge. develop agranulocytosis). Furthermore, in develop agranulocytosis). Furthermore, in the majority of our unsuccessfully rechal-the majority of our unsuccessfully rechallenged patients, the second blood dyscrasia lenged patients, the second blood dyscrasia occurred more rapidly, lasted longer and/or occurred more rapidly, lasted longer and/or was more severe than the first blood dyscra-was more severe than the first blood dyscrasia. Our data demonstrate that even pa-sia. Our data demonstrate that even patients in whom the indications are that tients in whom the indications are that clozapine was not causative in their blood clozapine was not causative in their blood dyscrasia (e.g. patients who develop blood dyscrasia (e.g. patients who develop blood dyscrasias after lengthy treatment) can ex-dyscrasias after lengthy treatment) can experience agranulocytosis on rechallenge. perience agranulocytosis on rechallenge.
Our results demonstrate how difficult it is Our results demonstrate how difficult it is to identify with any certainty patients to identify with any certainty patients whose blood dyscrasias are unrelated to whose blood dyscrasias are unrelated to clozapine, and the need for extreme clozapine, and the need for extreme vigilance when rechallenging any patient. vigilance when rechallenging any patient. However, we also demonstrated that pa-However, we also demonstrated that patients who do not develop a blood dyscrasia tients who do not develop a blood dyscrasia on rechallenge are likely to continue with on rechallenge are likely to continue with clozapine treatment: indeed, the majority clozapine treatment: indeed, the majority of all the rechallenged patients continued of all the rechallenged patients continued clozapine treatment, many for a number clozapine treatment, many for a number of years. Therefore, in a carefully selected of years. Therefore, in a carefully selected group rechallenge may well be justified if group rechallenge may well be justified if it is considered that the risks of withholding it is considered that the risks of withholding treatment are greater than the risks of treatment are greater than the risks of rechallenge. rechallenge.
